April 19, 2022
1 min watch
Save
Video: DIAMOND study provides ‘interesting data’ on hyperkalemia reduction
In this video, David E. Lanfear, MD, advanced HF specialist and program director of the Advanced Heart Failure Fellowship at the Henry Ford Health System in Detroit, spoke to Healio about two clinical trials presented at the American College of Cardiology Scientific Session.
Lanfear focused on the hypertrophic cardiomyopathy (HCM) study that showed “very good benefit” in terms of quality of life.
He also discussed the DIAMOND study, which provided “interesting data for heart failure” in a patiromer that could reduce hyperkalemia in patients with HF.
Reference:
- Szecsödy, P. Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND). Presented at: American College of Cardiology Scientific Session & Expo 2022; April 2-4, 2022; Washington, D.C.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Lanfear reports receiving research grants from and consulting or serving on an advisory board for Amgen, receiving research grants from Somalogic and consulting or serving on an advisory board for Abbott, Cytokinetics, DCRI, Janssen, Martin and Ortho Diagnostics.
Read more about